Видео ютуба по тегу Mcrpc

ADT Resistant Metastatic Prostate Cancer (mCRPC) - 2021 Prostate Cancer Patient Conference
ADT Resistant Metastatic Prostate Cancer (mCRPC) - 2021 Prostate Cancer Patient Conference
Perspectives in mCRPC in 2024
Perspectives in mCRPC in 2024
PARPi in mCRPC
PARPi in mCRPC
Ep. 10: How Has the mCRPC Treatment Landscape Changed?
Ep. 10: How Has the mCRPC Treatment Landscape Changed?
Metastatic Castration Resistant Prostate Cancer (mCRPC) – Inroads in Improved Outcomes
Metastatic Castration Resistant Prostate Cancer (mCRPC) – Inroads in Improved Outcomes
Overall Survival Data in mCRPC
Overall Survival Data in mCRPC
The Differences Between mCRPC and nmCRPC
The Differences Between mCRPC and nmCRPC
Point-Counterpoint: Management of mCRPC
Point-Counterpoint: Management of mCRPC
The evolving treatment landscape of mHSPC and mCRPC
The evolving treatment landscape of mHSPC and mCRPC
Prognostic biomarkers to guide treatment of mCRPC
Prognostic biomarkers to guide treatment of mCRPC
Monitoring Response of metastatic castration resistance prostate cancer (mCRPC)
Monitoring Response of metastatic castration resistance prostate cancer (mCRPC)
UROwebinar: New treatment options in mCRPC
UROwebinar: New treatment options in mCRPC
Role of Chemotherapy, Treatment Sequencing in mCRPC and Future Directions
Role of Chemotherapy, Treatment Sequencing in mCRPC and Future Directions
PROpel: Final OS of First-Line Abiraterone Plus Olaparib for mCRPC
PROpel: Final OS of First-Line Abiraterone Plus Olaparib for mCRPC
mCRPC: Sequencing Therapy
mCRPC: Sequencing Therapy
Treatment Approaches for Newly Diagnosed mCRPC
Treatment Approaches for Newly Diagnosed mCRPC
Nursing Support for mCRPC patients during radiopharmaceutical treatments
Nursing Support for mCRPC patients during radiopharmaceutical treatments
VISION: 177Lu-PSMA-617 in PSMA-positive mCRPC
VISION: 177Lu-PSMA-617 in PSMA-positive mCRPC
Support for continuing enzalutamide after mCRPC progression | Axel Merseburger
Support for continuing enzalutamide after mCRPC progression | Axel Merseburger
Emerging treatments for mCRPC
Emerging treatments for mCRPC